Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 10/20 | 0.53 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29893123 | 0.80 | LATS1 (0.50) | LATS1LATS2NAMPT | |
| SCHEMBL29893017 | 0.77 | KDM4C (0.54) | LATS1LATS2NAMPT | |
| SCHEMBL16410303 | 0.76 | ATR (0.47) | NAMPTKDM4ACYP1A2POLBMAPK1 | |
| SCHEMBL26177100 | 0.75 | LATS1 (0.76) | LATS1LATS2 | |
| SCHEMBL30765895 | 0.73 | NAMPT (0.43) | LATS1LATS2NAMPTCYP3A4CYP1A2 | |
| SCHEMBL31558539 | 0.73 | NAMPT (0.43) | LATS1LATS2NAMPTCYP3A4CYP1A2 | |
| SCHEMBL24964516 | 0.72 | DYRK1A (0.47) | LATS1LATS2NAMPTKDM4ACYP3A4 | |
| SCHEMBL30759308 | 0.72 | CACNA1H (0.51) | LATS1LATS2NAMPTKDM4ACYP3A4 | |
| SCHEMBL30661687 | 0.72 | DYRK1A (0.47) | LATS1LATS2NAMPTKDM4ACYP3A4 | |
| SCHEMBL30759244 | 0.72 | LATS1 (0.46) | LATS1LATS2NAMPTKDM4ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313308-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230098872-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022204452-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230098872-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | LATS1 1576/4885LATS2 648/4885NAMPT 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.